Edit
Comet Therapeutics
https://comettherapeutics.com/Last activity: 06.09.2021
Probably Closed - Reference to comettherapeutics.com
CoEnzyme A (CoA) is essential to numerous cellular processes including the metabolism of fatty acids, amino acids and sugars, the regulation of gene expression, and the proper functioning of the TCA cycle and mitochondrial health, which generates the energy all cells need to live.
There are many genetic, rare metabolic disorders that are CoA related. In addition, dysregulated CoA metabolism is a key factor in diseases as diverse as cancer, fatty liver and neurological disorders. While CoA has been in biochemistry textbooks for 70 years, there are no therapies to restore dysregulated coenzyme A metabolism.
Comet Therapeutics addresses these profound unmet medical needs with its CoEnzyme Metabolism (CoMET™) Platform.
There are many genetic, rare metabolic disorders that are CoA related. In addition, dysregulated CoA metabolism is a key factor in diseases as diverse as cancer, fatty liver and neurological disorders. While CoA has been in biochemistry textbooks for 70 years, there are no therapies to restore dysregulated coenzyme A metabolism.
Comet Therapeutics addresses these profound unmet medical needs with its CoEnzyme Metabolism (CoMET™) Platform.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $57M
Founded date: 2018
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.08.2019 | Series A | $28.5M | Canaan Par... |
| 20.06.2019 | Series A | $28.5M | - |
Mentions in press and media 7
| Date | Title | Description |
| 06.09.2021 | VectivBio expands drug pipeline | VectivBio (Nasdaq: VECT) is a global, clinical-stage biotechnology company focused on discovering, developing, and commercialising innovative treatments for severe rare conditions. to expand its drug pipeline. The company has acquired Comet... |
| 21.06.2019 | How Slack Made Other Startup CEOs Wealthy: Term Sheet | SLACK SOARS Slack killed it. Paid Content You can't secure what you can't see From ExtraHop Yesterday, I noted that Accel had a big windfall thanks to Slack’s public market debut. But I read an interesting story in Forbes that talks about h... |
| 20.06.2019 | Who’s Getting Rich From Slack’s Direct Listing: Term Sheet | GETTING RICH As Slack makes its public debut today, let’s take a look at who stands to win big. Paid Content Keeping business secure in the age of digital privacy From ExtraHop Now, at Slack’s debut, Accel stands to make about $3.1 billion ... |
| 20.06.2019 | Comet Therapeutics Raises $28.5M Series A | CAMBRIDGE, MA, Comet Therapeutics has raised $28.5 million in Series A funding. >> Click here for more funding data on Comet Therapeutics >> To export Comet Therapeutics funding data to PDF and Excel, click here Comet The... |
| 19.06.2019 | Comet Therapeutics Raises $28.5M in Series A Financing | Comet Therapeutics, a Cambridge, Mass.-based company built around the ability to re-engineer Coenzyme A (CoA)-related metabolism, raised $28.5m in Series A funding. The round was co-led by Canaan and existing investor Sofinnova Partners, wi... |
| 19.06.2019 | Daily funding roundup - June 19th, 2019 | Whitebox raised $5M; Enboarder landed $8M; Text IQ closed $12.6M; Valtix secured $14M Defendify: Defendify is an all-in-one, SaaS-delivered cybersecurity solution designed specifically for small businesses. Defendify has raised $1.6M in pre... |
| 19.06.2019 | Comet Therapeutics Raises $28.5 Million Series A Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Comet Therapeutics, a company built around the unique ability to re-engineer Coenzyme A (CoA)-related metabolism, has raised $28.5 million in Series A funding to develop a broad portfolio of drug candidate... |